Abstract
Cancer Most searches for druggable tumor-specific antigens (TSAs) start with an examination of peptides derived from protein-coding exons. Laumont et al. took a different approach and found numerous TSAs that derived from aberrant expression of noncoding sequences in murine cell lines and in B-lineage acute lymphoblastic leukemia and lung cancer patient samples. They validated the immunogenicity and efficacy of TSA vaccination for select antigens in mouse models of cancer. Noncoding regions are a potentially rich source of TSAs that could greatly expand the number of targetable antigens across different cancers, including those with low mutational burdens. Sci. Transl. Med. 10 , eaau5516 (2018).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
